We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Hyperactive Cysteine Sites Identified by New Quantitative Reactivity Technique

By LabMedica International staff writers
Posted on 14 Dec 2010
A publication described a new method for determining active regions on enzymes and other proteins by using specific probes in a fashion that discriminated between high and low affinity amino acid sites.

Investigators at the Scripps Research Institute (La Jolla, CA, USA) initially used the new technology to study the reactivity of cysteine residues in enzymes. More...
Cysteine is one of the most reactive of the amino acids and is often critically involved in determining the three-dimensional shape of protein molecules.

Two types of cysteine-specific probes were used. One probe bound to cysteine with high affinity while the other was less avid. This meant that by strictly controlling the concentration of the probe, they could determine whether it was binding to a particularly active or inactive cysteine site.

The investigators reported in the November 17, 2010, online edition of the journal Nature that they tested the technique on proteins found within a human breast cancer-cell line. They were able to identify and locate more than 800 cysteine sites on 522 proteins. For more than 90% percent of these cysteine sites the low and high concentration probes showed correspondingly low and high levels of labeling, indicating that the cysteine residues had ordinary reactivity. The other 10% of cysteine sites demonstrated a constant level of labeling for both low and high concentration probes, indicating that they were hyperreactive.

"What we have needed is a more efficient method to find and quantitatively analyze reactive sites,” said senior author Dr. Benjamin F. Cravatt, professor of chemical biology and physiology at the Scripps Institute, "not just for one protein in a purified sample but for a large set of proteins in their natural setting, such as within a whole cell or tissue.”

"It lets us find functional sites on proteins more efficiently than before, and that is going to be helpful not only for characterizing unknown proteins, but also for finding new sites of importance on already-characterized proteins. This is a relatively precise and straightforward method for screening designed proteins for functional properties,” said Dr. Cravatt. "It could be very useful for creating new enzyme catalysts for basic research and industrial applications.”

Related Links:

Scripps Research Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.